Company Overview of Laidlaw & Company (UK) Ltd.
Laidlaw & Company (UK) Ltd. provides investment banking and wealth management services to institutions and individuals in the United States and the United Kingdom. Its investment banking services include capital raising through placement of equity with institutional and high net worth retail investors; placement of debt and mezzanine capital with institutional investors; acquisition financing; arrangement of national exchange listings; the United States trading markets; AIM-listed transactions in the United Kingdom market; and initial public offerings. The company’s investment banking services also comprise advisory services on acquisitions, divestitures, fairness opinions, financial restruc...
546 5th Avenue
New York, NY 10036
Key Executives for Laidlaw & Company (UK) Ltd.
Managing Partner and Head of Capital Markets
Executive Director of Investment Banking and Head of Laidlaw Private Equity
Senior Managing Director, Private Placements
Compensation as of Fiscal Year 2015.
Laidlaw & Company (UK) Ltd. Key Developments
Laidlaw & Co. (UK) Ltd. Announces Executive Changes
Apr 21 15
Laidlaw & Co. (UK) Ltd. announced the expansion of its Institutional Equities distribution platform with the appointments of Kris Tomasulo as a Managing Director for Institutional Equity Sales and Robert Baumann as Head of Institutional Equity Trading. Kris and Bob will be joining the New York office. Laidlaw has also made two new senior capital market hires in Boston, bringing on Jim Molloy as a Managing Director covering Specialty Pharmaceuticals and Biotechnology stocks and Matt Dormer as a Managing Director in Investment Banking. Kris Tomasulo will join Laidlaw's Institutional Equity Sales team. He joins Laidlaw from Sterne Agee & Co., where he was most recently working with the healthcare team. Kris previously managed equity funds at Merus Capital Partners, Scoggin Capital, and The Galleon Group. At Galleon, Kris co-managed The Galleon Healthcare Fund, where he led an investment team of 5 professionals. Kris brings deep relationships in the healthcare financial community and will increase the penetration of Laidlaw's research and other product offerings in the market. Bob Baumann will assume the role of Head of Institutional Equity Trading. Prior to Laidlaw, Bob ran the institutional sales and trading desk at Summer Street Research Partners. With his 18 years of experience, Bob brings extensive healthcare trading knowledge along with deep institutional buy-side relationships to Laidlaw. Bob began his career at Banc of America Securities and has worked at Goldman Sachs, Leerink Swann, and Sanford Bernstein, where he successfully built and ran their healthcare sector trading platform for eight years. Jim Molloy brings over 15 years of sell-side experience to Laidlaw, having covered Specialty Pharmaceuticals and Biotechnology for a diverse group of Wall Street investment banks. Prior to Laidlaw, Jim was a Managing Director at Summer Street Research Partners and Janney Montgomery Scott. Prior to that he was a Senior Analyst at ThinkEquity Partners, Caris & Company, Oppenheimer, and Leerink Swann & Company. Jim has been ranked by Forbes Starmine for earnings accuracy. Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes.
Laidlaw & Co. (UK) LTD Hires Patrick Gallagher as Managing Director and Head of Healthcare Sales
Sep 23 14
Laidlaw & Co. (UK) LTD announced the addition of Patrick Gallagher to the company's ranks as Managing Director and Head of Healthcare Sales. Mr. Gallagher co-founded Black Diamond Research, LLC in 2001. Currently Patrick serves as a strategic consultant for Kinex Pharmaceuticals. Mr. Gallagher also serves on the board of directors for BioSig Technologies Inc.
Laidlaw & Co. LTD (UK) Announces Expansion of San Francisco, California Office; Relocates Ron Zuckerman, Managing Director to San Francisco Office
Feb 6 14
Laidlaw & Co. LTD (UK) announced the expansion of the company's San Francisco, California office and the forthcoming relocation to 55 Second Street in the iconic KMPG building. The company has added 6 employees, bringing the total Laidlaw presence in San Francisco to 10.
As part of this process, Ron Zuckerman, Managing Director, has relocated to Laidlaw's San Francisco office to help drive the expansion. Mr. Zuckerman had previously worked out of the Laidlaw New York office and has over 15 years of experience. Ron Zuckerman will continue to service all his existing high net worth clients and his contact information will remain the same.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|